Share on LinkedInShare on LinkedIn

ARTICLE · 18 FEBRUARY 2022

Diagnostic Test Kit: Integration Of Patented Technologies

Since the beginning of the pandemic, the Food and Drug Administration (FDA) has been at a rapid pace in evaluating COVID-19 related diagnostic tests, amongst which include those that utilize patented technologies.

CanadaIntellectual Property

Since the beginning of the pandemic, the Food and Drug Administration (FDA) has been at a rapid pace in evaluating COVID-19 related diagnostic tests, amongst which include those that utilize patented technologies. As of January 2022, the FDA has authorized over 400 COVID-19 related tests and collection kits, including over 200 molecular tests, over a dozen at-home tests performed at user's home with a self-collected sample, over 60 home collection tests and kits where samples are collected at home and sent to a lab for processing, and over 50 point-of-care tests that quickly return a result at a health care setting.

Diagnostic test kits are often simple to operate for the home users and health care providers. However, beneath the veneer of simplicity in operation is the integration of a myriad of different technologies. For example, Lucira" CHECK-IT COVID-19 Test Kit has received FDA Emergency Use Authorization for nonprescription over-the-counter home use as of

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from